In this article, we will list the 5 Hot Biotech Stocks Under $5 to Buy. Please visit 10 Hot Biotech Stocks Under $5 to Buy if you’d like to see an extended list and the methodology behind it.
5. Opus Genetics, Inc. (NASDAQ:IRD)
While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy.
Fresh coverage initiations and a series of positive data readouts have kept analyst attention firmly on this clinical-stage gene therapy company.
On June 4, 2026, Guggenheim initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with a “Buy” rating and a $16 price target, the most bullish call among covering analysts.
That followed Leerink’s initiation on May 21, 2026, with an “Outperform” rating and a $10 price target. Leerink described Opus Genetics, Inc. (NASDAQ:IRD) as a clinical-stage company developing gene therapies for inherited retinal disorders and called the first patient data for OPGxBEST1 “encouraging,” pointing to a market opportunity Opus estimates at up to $9 billion.
The firm said even conservative projections for OPGxLCA5 and OPGxBEST1 support a compelling risk/reward profile and believes Opus Genetics, Inc. (NASDAQ:IRD) is well capitalized for its commercial-stage transition.
Meanwhile, on May 13, 2026, Citizens trimmed its price target on Opus Genetics, Inc. (NASDAQ:IRD) to $11 from $12 while keeping an “Outperform” rating. The firm noted that recent ARVO data continue to support OPGx-LCA5’s durable efficacy and favorable safety profile, with pediatric results aligning with adult outcomes. FDA Rare Disease Endpoint Pathway acceptance and a manageable pivotal study design were cited as meaningful de-risking factors, with upcoming September data from the BEST1 study flagged as the next key catalyst.
Broader analyst sentiment, meanwhile, remains firmly positive. Seventeen analysts cover the stock with bullish ratings and a consensus mean price target of $10.00.
Opus Genetics, Inc. (NASDAQ:IRD) is engaged in the research and development of ophthalmic biopharmaceutical products, with a focus on developing and commercializing therapies for several eye disorders.
4. Fate Therapeutics, Inc. (NASDAQ:FATE)
Fate Therapeutics, Inc. (NASDAQ:FATE), featuring a year-to-date gain of 102.04% and upside potential of 228.30%, secures a spot on our list of hot biotech stocks under $5 to buy.
Fresh Phase 1 data presented at a major rheumatology conference gave analysts fresh reason to stay constructive on Fate Therapeutics, Inc. (NASDAQ:FATE)’s lead off-the-shelf cell therapy program.
On June 8, 2026, H.C. Wainwright reiterated a “Buy” rating and $7.00 price target on Fate Therapeutics following updated Phase 1 data presented at the annual EULAR meeting for FT819, its iPSC-derived, off-the-shelf CD19 CAR-T therapy.
The data covered 16 heavily pretreated systemic lupus erythematosus patients with a median disease duration of 7.6 years, seven median prior treatments, and a mean baseline SLEDAI-2K score of 13.6. FT819 with bendamustine conditioning in seven patients produced deeper and more consistent B-cell depletion and greater FT819 expansion compared to cyclophosphamide conditioning in six patients. B-cell receptor sequencing showed a 74% to 96% reduction in the top 50 most expanded clones at baseline across all five patients analyzed, with dominant clones not reappearing at any time point up to 12 months.
No patients experienced Grade 3 or higher cytokine release syndrome, supporting the potential for outpatient administration. FT819 with less-intensive conditioning showed early and sustained clinical improvement, with a trend toward more favorable responses with bendamustine conditioning.
H.C. Wainwright said the results support the potentially registrational Phase 2 RECLAIM-LN trial, which evaluates FT819 with bendamustine conditioning in patients with refractory moderate-to-severe SLE with lupus nephritis. The firm expects additional clinical, regulatory, and operational updates for FT819 in the second half of 2026, Investing.com reported.
Fate Therapeutics, Inc. (NASDAQ:FATE) is a California-based clinical-stage biopharmaceutical company that focuses on the development of programmed cellular immunotherapies for people living with cancer and immune disorders.
3. Pyxis Oncology, Inc. (NASDAQ:PYXS)
While Pyxis Oncology, Inc. (NASDAQ:PYXS) has gained 54.78% year-to-date, analysts continue to see 293.30% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy.
That analyst conviction is rooted in a busy clinical calendar, with key data readouts from Pyxis Oncology, Inc. (NASDAQ:PYXS)’s lead program expected across the second and third quarters of 2026.
On May 14, 2026, Pyxis Oncology, Inc. (NASDAQ:PYXS) reported first-quarter financial results and provided an update on its micvotabart pelidotin (MICVO) development program.
Pyxis Oncology, Inc. (NASDAQ:PYXS) said it remains on track to share updated monotherapy data in mid-year 2026, focusing on second-line-plus recurrent or metastatic head and neck squamous cell carcinoma patients treated at or below a dose cap implemented in December 2025. Updated combination data from the Phase 1/2 study of MICVO alongside Merck’s pembrolizumab, focused on first-line patients in the same indication, is expected in the second half of 2026.
Enrollment for the monotherapy dose expansion study was completed in the first quarter of 2026, and a protocol amendment permitting adjusted ideal bodyweight dosing has been approved, with that approach selected as the go-forward only if it offers a superior profile to dose capping.
On the financials, Pyxis Oncology, Inc. (NASDAQ:PYXS) posted a net loss of $23.3 million, or $0.37 per share, for the quarter ended March 31, 2026. Research and development expenses rose to $20.0 million from $17.0 million a year earlier, driven largely by higher clinical trial costs. The company held $42.5 million in cash and short-term investments as of March 31, 2026, which it said is sufficient to fund operations into the fourth quarter of 2026.
Nearly all covering analysts remain bullish as of June 8, 2026, with a consensus price target of $7.00.
Pyxis Oncology, Inc. (NASDAQ:PYXS) is a clinical-stage company developing therapeutics for difficult-to-treat cancers, with its lead ADC candidate, MICVO, targeting Extradomain-B Fibronectin to directly kill cancer cells and mobilize anti-tumor immune responses.
2. InflaRx N.V. (NASDAQ:IFRX)
While InflaRx N.V. (NASDAQ:IFRX) has gained 82.18% year-to-date, analysts continue to see 385.90% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy.
That analyst conviction only strengthened by mid-May, with two firm upgrades and target raises arriving back-to-back following a corporate update and first-quarter results.
On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to “Strong Buy” from “Outperform” and raised its price target to $9 from $7.
The firm cited a constructive view of InflaRx N.V. (NASDAQ:IFRX)’s izicopan program in ANCA-associated vasculitis, pointing to a recent $150 million financing that extends the runway into proof-of-concept development. The analyst noted preclinical and early clinical signals suggesting potentially improved potency, reduced hepatotoxicity risk, and simpler dosing compared to avacopan, while also flagging the program’s positioning to benefit from validated C5aR biology and broader complement pathway opportunities across renal indications.
That followed a target raise from H.C. Wainwright two days earlier.
On May 11, 2026, Wainwright’s analyst Matthew Keller lifted the firm’s price target to $8 from $6 while keeping a “Buy” rating, citing InflaRx N.V. (NASDAQ:IFRX)’s adjusted clinical focus on ANCA-associated vasculitis and inflammatory renal diseases, as well as the potential partnering of its hidradenitis suppurativa program following a recent corporate update.
Broader analyst sentiment remains firmly positive. Six of seven covering analysts hold a bullish view, and InflaRx N.V. (NASDAQ:IFRX) carries a consensus median price target of $8.95, even as shares currently trade under $2.
InflaRx N.V. (NASDAQ:IFRX) discovers and develops inhibitors using C5a technology in Germany and the United States.
1. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), featuring a year-to-date gain of 52.77% and upside potential of 987.00%, secures a spot on our list of hot biotech stocks under $5 to buy.
A clinical-stage biopharmaceutical company focused on bringing suicide-prevention drugs to market, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), just closed a capital raise that provides it with a fresh runway to push its pipeline forward.
On June 4, 2026, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) closed an underwritten public offering of its common stock at $3.50 per share, generating gross proceeds of approximately $22.3 million before underwriting discounts, commissions, and other offering expenses. That figure reflects the exercise of the underwriters’ option to purchase additional shares. The company said it plans to use the net proceeds for working capital and general corporate purposes.
The closing followed shortly after the pricing announcement.
On June 3, 2026, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) priced 5,714,286 shares at $3.50 each, with gross proceeds initially projected at approximately $20.0 million, or up to $23.0 million if the underwriters exercised their 30-day option to purchase up to an additional 857,142 shares in full. BTIG, LLC acted as lead bookrunning manager, with Lucid Capital Markets, LLC serving as joint bookrunning manager.
The offering process began on June 2, 2026, when NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its intention to launch the deal, subject to market conditions.
“In an era where an American dies from suicide every 11 minutes, we feel honored to be part of the potential solution,” said Chairman and CEO Jonathan Javitt, MD, MPH.
Founded in 2015 and headquartered in Wilmington, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies targeting central nervous system disorders, including severe suicidal depression, post-traumatic stress disorder, and bipolar depression.
While we acknowledge the potential of NRXP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NRXP and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Commodity Stocks to Buy in 2026 and 10 Best AI Infrastructure Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
